

DAFTAR PUSTAKA

- Almond J. Clemens J., Engers H., Halstead S., Khiem H.B., Pabloz-Mendez A., et al. 2002. Accelerating the development and introduction of dengue vaccine for poor children, 5-8 December 2001, Ho Chi Minh City, VietNam. *Vaccine*, 20: p. 3043-3046.
- Amin P., Bhandare S., and Srivastava A. 2001. Dengue, Dengue Haemorrhagic Fever, Dengue Shock Syndrome. http://www.bhj.org/journal/2001_4303_july01/review_380.htm 27-04-2004.
- Anderson R., Wang S., Osiowy C. and Issekutz A.C. 1997. Activation of Endothelial Cells via Antibody-enhanced Dengue Virus infection of Peripheral Blood Monocytes. *J. Virol.*, 71 (6): p. 4226-4232.
- Anna Durbin, Phase I
<http://clinicaltrials.gov/ct/gui/info/phac.jsessionid=269319642B5C64CBEB7BFAB09B4BB133>, 9 oktober 2004).
- Bancroft W.H., Top, Jr F.H., Eckels K.H., Anderson, Jr. J.H., McCown J.M., and Russell P.K. 1981. Dengue-2 vaccine: virological, immunological, and clinical responses of six yellow fever-immune recipients. *Infect Immun.*, 31 (2): p. 698-703.
- Bhamarapavati N. and Yoksan S. 1997. Live attenuated tetravalent dengue vaccine. In D.J. Gubler and G. Kune: *Dengue and Dengue Hemorrhagic Fever*. Cambridge: University press. p. 367-377.
- _____. 2000. Live attenuated tetravalent dengue vaccine. *Vaccine*, 18 (2): p. 44-47.
- Blaney J.E. Jr, Manipon G.G., Firestone C.Y., Johnson D.H., Hanson C.T., Murphy B.R., et al. 2003. Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells. *Vaccine*, 21 (27-30): p. 4317-27.
- Blaney Jr J.E., Johnson D.H., Firestone C.Y, Hanson C.T., Murphy B.R., and Whitehead S.S. 2001. Chemical Mutagenesis of Dengue Virus Type 4 Yields Mutant Viruses Which Are Temperature Sensitive in Vero Cells or Human Liver Cells and Attenuated in Mice. *Journal of Virology*, 75 (20): p. 9731-40.
- Bosch I., Khaja K., Estevez L., Raines G., Melichar H., Warke R.V., et al. 2002. Increased Production of Interleukin-8 in Primary Human Monocytes and in

- Human Epithelial and Endothelial Cell Lines after Dengue Virus Challenge. *Journal of Virology*, 76 (11): p. 5588-5597.
- Bosch I. 2003. Gene Expression of Host Cells Infected with Dengue Virus. <http://www.ipk.sld.cu/curso-dengue-memorias/conferencias-magistrales/23.pdf>, 28-01-2005.
- Bray M., Men R., and Lai C.J. 1996. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge. *J. Virol.*, 70 (6): p. 4162-4166.
- Bumi C., Rantam F.A, Soegijanto S., dan Hamid I.S. 2004. Determinan virulensi virus dengue. In Soegeng Soegijanto: *Demam berdarah dengue: tinjauan dan temuan baru di era 2003*. Surabaya: Airlangga University Press. p. 91-97.
- Catteau A., Roue G., Yuste V.J., Susin S.A., and Despres P. 2003. Expression of dengue ApoptoM sequence results in disruption of mitochondrial potential and caspase activation. *Biochimie*, 85 (8): pp. 789-793.
- CDS.1999. Regional guidenesson Dengue/DHF prevention and control. <http://www.org/whosea/cds/index.htm> , 13-10-2004.
- Cella M., Salio M., Sakakibara Y., Langen H., Julkunen I., and Lanzavecchia A. 1999. Maturation, activation, and protection of dendritic cells induced by double stranded RNA. *J. Exp. Med.*, 189 (5): p. 821-829.
- Chambers T.J., Liang Y., Droll D.A., Schlesinger J.J, Davidson A.D., Wright P.J., et al. 2003. Yellow Fever Virus/Dengue-2 Virus and Yellow Fever Virus/Dengue-4 Virus Chimeras: Biological Characterization, Immunogenicity, and Protection against Dengue Encephalitis in the Mouse Model. *Journal of Virology*, 77 (6): p. 3655-3668.
- Chang D.M. and Shaio M.F.1994. Production of interleukin-1 (IL-1) and IL-1 inhibitor by human monocytes exposed to dengue virus. *Journal of Infectious Diseases*, 170 (4): pp. 811-817.
- Chang G.J. 1997. Molecular biology of dengue viruses. In D.J. Gubler and G. Kune: *Dengue and Dengue Hemorrhagic Fever*. Cambridge: University press. p. 175-198.
- Chang G.J., Kuno G., Purdy D.E., and Davis B.S. 2004. Recent advancement in flavivirus vaccine development. *Expert Rev Vaccines.*, 3 (2): p. 199-220.
- Chang H.H., Shyu H.F., Wang Y.M., Sun D.S., Shyu R.H., Tang S.S., et al. 2002. Facilitation of cell adhesion by immobilized dengue viral nonstructural

protein 1 (NS1): Arginine-glycine-aspartic acid structural mimicry within the dengue viral NS1 antigen. *Journal of Infectious Diseases*, 186 (6): pp. 743-751.

Chao D.Y., Lin T.H., Hwang K.P., Huang J.H., Liu C.C., and King C.C. 1998. dengue hemorrhagic fever epidemic in Taiwan. : [//www.cdc.gov/ncidod/EID/vol10no3/02-0518.htm](http://www.cdc.gov/ncidod/EID/vol10no3/02-0518.htm), 27-04-2004.

Chaturvedi U.C., Elbishbishi E.A., Agarwal R., and Mustafa A.S. 2001. Cytotoxic factor-autoantibodies: possible role in the pathogenesis of dengue haemorrhagic fever FEMS. *Immunology & Medical Microbiology*, 30 (3): pp. 181-186.

Chen Y.C. and Wang S.Y. 2002. Activation of Terminally Differentiated Human Monocytes/Macrophages by Dengue Virus: Productive Infection, Hierarchical Production of Innate Cytokines and Chemokines, and the Synergistic Effect of Lipopolysaccharide. *Journal of Virology*, 76 (19): p. 9877-9887.

Chen Y.P., Maguire T., Hileman R.E., Fromm J.R., Esko J.D., Linhardt R.J. et al. 1997. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. *Nature Medicine*, 3 (8): p. 866-871.

Chung N.P.Y., Chen Y., Chan V.S.F., TAM P.K.H., and Lin C.L.S. 2004. Dendritic cells: sentinels against pathogens. *Histology and Histopathology*, 19 (1): p. 317-314.

Chungue E., Poli L., Roche C., Gestas P., Glaziou P., and Markoff L.J. 1994. Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection. *J Infect Dis.*, 170 (5): p. 1304-7.

Craig S., Myat Thu H., Lowry K., Wang X.F., Holmes E.C., and Aaskov J. 2003. Diverse dengue type 2 virus population contain recombinant and both parental viruses in a single mosquito host. *Journal of Virology*, 77 (7): p. 4463-4467.

Diamond M.S., Edgil D., Roberts T.G., Lu B., and Harris E. 2000. Infection of Human Cells by Dengue Virus Is Modulated by Different Cell Types and Viral Strains. *Journal of Virology*, 74 (17): p. 7814-7823.

Dos Santos F.B., Miagostovich M.P., Nogueira M.R., Schatmayr H.G., Riley L.W., Harris E. Analysis of recombinant Dengue virus polypeptides for Dengue diagnosis and evaluation of the humoral immune response. *Am. J. Trop. Med. Hyg.*, 71(2): pp. 144-152

- Durbin A.P., Karron R.A., Sun W., Vaughn D.W., Reynolds M.J., Perreault J.R., et al. 2001. Attenuation and Immunogenicity in Humans of Live Dengue Virus type-4 Vaccine Candidate with 30 Nucleotide Deletion in its 3'-Untranslated Region. *Am. J. Trop. Med. Hyg.*, 65 (5): p. 405-413.
- Eckels K.H. and Putnak R. 2003. Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines. *Adv Virus Res*, 61: p. 395-418.
- Eckels K.H., Scott R.M., Bancroft W.H., Brown J., Dubois D.R., Summers P.L., et al. 1984. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells. *Am J Trop Med Hyg.*, 33 (4): p. 684-9.
- Edelman R., Wasserman S.S., Bodison S.A., Putnak R.J., Eckels K.H., Tang D., et al. 2003. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. *Am J Trop Med Hyg.*, ;69(6 Suppl):48-60.
- Espina L.M., Valero N.J., Hernandez J.M., and Mosquera J.A. 2003. Increased apoptosis and expression of tumor necrosis factor α caused by infection of cultured of human monocytes with dengue virus. *Am. J. Trop. Med. Hyg.*, 68 (1): p. 48-53.
- Gagnon S.J., Ennis F.A., and Rothman A.L. 1999. Bystander Target Cell Lysis and Cytokine Production by Dengue Virus-Specific Human CD4⁺ Cytotoxic T-Lymphocyte Clones. *Journal of Virology*, 73 (5): p. 3623-3629.
- Gagnon S.J., Mori M., Kurane I., Green S., Vaughn D.W., Kalayanarooj S., et al. 2002. Cytokine gene expression and protein production in peripheral blood mononuclear cells of children with acute dengue virus infections. *J Med Virol*, 67 (1): p. 41-6.
- Green S., Vaughn D.W., Kalayanarooj S., Nimmannitya S., Suntayakorn S., Nisalak A., et al. 1999. Early Immune Activation in Acute Dengue Illness Is Related to Development of Plasma Leakage and Disease Severity. *The Journal of Infectious Diseases*, 179: p. 755-762.
- Green S., Kurane I., Edelman R., Tacket C.O, Eckels K.H., Vaughn D.W., Hoke Jr C.H., and Ennis F.A. 1993. Dengue virus-specific human CD4⁺ T-lymphocyte responses in a recipient of an experimental live-attenuated dengue virus type 1 vaccine: bulk culture proliferation, clonal analysis, and precursor frequency determination. *J. Virol.*, 67 (10): p. 5962-67.
- Gubler D.J. 1998. Dengue and dengue hemorrhagic fever. *Clinical Microbiology Reviews*, 11(3): p. 480-496.

- Guirakhoo F., Arroyo J., Pugachev K.V., Miller C., Zhang Z.X., Weltzin R., et al. 2001. Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine. *Journal of Virology*, 75 (16): p. 7290-7304.
- Guirakhoo F., Pugachev K., Arroyo J., Miller C., Zhang Z.X., Weltzin R., et al. 2002. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. *Virology*, 298 (1): p. 146-59.
- Guirakhoo F., Pugachev K., Zhang Z., Myers G., Levenbook I., Draper K., et al. 2004. Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formulations in Nonhuman Primates. *Journal of Virology*, 78 (9): p. 4761-4775
- Guirakhoo F., Weltzin R., Chambers T.J., Zhang Z.X., Soike K., Ratterree M., Arroyo J., et al. 2000. Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus Is Immunogenic and Protective in Nonhuman Primates. *Journal of Virology*, 74 (12): p. 5477-5485.
- Guirakhoo F., Zhang Z., Myers G., Johnson B.W., Pugachev K., Nichols R., et al. 2004. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. *J Virol.*, 78 (18): p. 9998-10008.
- Guzman M.G. 1998. Advances in the development of a vaccine against dengue. *Acta Cient Venez.*, 49 Suppl 1: p. 38-45
- Guzman M.G., Rodriguez R., Rodriguez R., Hermida L., Alvarez M., Lazo L., et al. 2003. Induction of neutralizing antibodies and partial protection from viral challenge in *Macaca Fascicularis* immunized with recombinant Dengue 4 virus envelope glycoprotein expressed in *Pischia pastoris*. *Am. J. Trop. Med. Hyg.*, 69 (2): p. 129-134.
- Gwinn W., Sun W., Innis B.L., Caudill J., and King A.D. 2003. Serotype-specific TH1 responses in recipients of two doses of candidate live-attenuated dengue virus vaccines. *American Journal of Tropical Medicine & Hygiene*, 69 (6): p. 39-47 (Suppl. S).
- Hadinegoro A.R.H., Soegijanto S., Wuryahadi S., dan Suroso T. 1998. Tatalaksana demam dengue/demam berdarah dengue pada anak. In Sri Rezeki H. Hadinegoro dan Hindra Irawan Satari: *Demam berdarah dengue*. Jakarta: FKUI. p. 82-84.

- Halstead S.B. 1988. Pathogenesis of dengue: challenges to molecular biology. *Science*, 239 (4839): p. 476-81.
- Halstead S.B. 1997. Epidemiology of dengue and dengue hemorrhagic fever. In D.J. Gubler and G. Kune: *Dengue and Dengue Hemorrhagic Fever*. Cambridge: University press. p. 23-44.
- Halstead S.B. and Marchette N.J. 2003. Biologic properties of dengue viruses following serial passage in primary dog kidney cells: Studies at the University of Hawaii. *American Journal of Tropical Medicine & Hygiene*, 69 (6): pp. 5-11 (Suppl. S).
- Hanley K.A., Manlucu L.R., Manipon G.G., Hanson C.T., Whitehead S.S., Murphy B.R., et al. 2004. Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity. *Vaccine*, 22 (25-26): p. 3440-8.
- Hanley K.A., Lee J.J., Blaney, Jr J.E., Murphy B.R., and Whitehead S.S. 2002. Paired Charge-to-Alanine Mutagenesis of Dengue Virus Type 4 NS5 Generates Mutants with Temperature-Sensitive, Host Range, and Mouse Attenuation Phenotypes. *Journal of Virology*, 76 (2): p. 525-531.
- Harrison V.R., Eckels K.H., Sagartz J.W., and Russell P.K. 1977. Virulence and immunogenicity of a temperature-sensitive dengue-2 virus in lower primates. *Infect Immun.*, 18 (1): p. 151-6.
- Henke A. 2002. DNA immunization--a new chance in vaccine research?. *Med Microbiol Immunol (Berl.)*, 191 (3-4): p. 187-90.
- Ho L.J., Wang J.J., Shaio M.F., Kao C.L., Chang D.M., Han S.W., et al. 2001. Infection of human dendritic cells by Dengue virus causes cell maturation and cytokine production. *Journal of Immunology*, 166 (3): pp. 1499-1506.
- Huang C.Y.H, Butrapet S., Tsuchiya K.R., Bhamarapavati N., Gubler D.J., and Kinney R.M. 2003. Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development. *Journal of Virology*, 77 (21): p. 11436-11447.
- Huang C.Y.H., Butrapet S., Pierro D.J., Chang G.J., Hunt A.R., Bhamarapavati N., et al. 2000. Chimeric Dengue Type 2 (Vaccine Strain PDK-53)/Dengue Type 1 Virus as a Potential Candidate Dengue Type 1 Virus Vaccine, *Journal of Virology*, 74 (7): p. 3020-3028.

- Innis B.L. 1997. Antibody responses to dengue virus infection. In D.J. Gubler and G. Kune: *Dengue and Dengue Hemorrhagic Fever*. Cambridge: University press. p. 221-243.
- Jaiswal S., Khanna N., and Swaminathan S. 2003. Replication-Defective Adenoviral Vaccine Vector for the Induction of Immune Responses to Dengue Virus Type 2. *Journal of Virology*, 77 (23): p. 12907-12913.
- Jan J.T., Chen B.H., Ma S.H., Liu C.I., Tsai H.P., Wu H.C., et al. 2000. Potential Dengue Virus-Triggered Apoptotic Pathway in Human Neuroblastoma Cells: Arachidonic Acid, Superoxide Anion, and NF- κ B Are Sequentially Involved. *Journal of Virology*, 74 (18): p. 8680-8691.
- Jimenez R.O. and da Fonseca B.A.L. 2000. Recombinant plasmid expressing a truncated dengue-2 virus E protein without co-expression of prM protein induces partial protection in mice. *Vaccine*, 19 (6): p. 648-654.
- Jirakanjanakit N., Khin M.M., Yoksan S., and Bhamarapavati N. 1999. Dynamics of Susceptibility and Transmissibility of the Live Attenuated Candidate Vaccines Dengue-1 PDK13, Dengue-3 PGMK30F3, and Dengue-4 PDK 48 After Oral Infection In *Aedes Aegypti*. *Am. J. Trop. Med. Hyg.* 61 (4): p. 672-676.
- Johnson B.W., Chambers T.V., Crabtree M.B., Guirakhoo F., Monath T.P., and B.R. Miller. 2004. Analysis of The Replication Kinetics of ChimeraVaxtm DEN1,2,3,4 Tetravalent Virus Mixture In *Aedes aegypti* by Real-Time Reverse Transcriptase-Polymerase Chain Reaction. *Am. J. Trop. Med. Hyg.*, 70 (1): p. 89-97.
- Kanesa-Thanan N., Edelman R., Tacket C.O. Wasserman S.S., Vaughn D.W., Coster T.S., et al. 2003. Phase 1 Studies of Walter reed Army Institute of Research Candidate Attenuated Dengue Vaccines: Selection of Safe and Immunogenic Monovalent vaccines. *Am. J. Trop. Med. Hyg.*, 69(6 suppl): p. 17-23.
- Kankirawatana P., Chokephaibulkit K., Puthavathana P., Yoksan S., Apintanapong S., and Pongthapisit V. 2000. Dengue infection presenting with central nervous system manifestation. *J Child Neurol.*, 15 (8): p. 544-7
- Karnen Garna Baratawidjaja. 2000. *Imunologi Dasar*. Jakarta: FKUI. p. 8.
- Keelapang P., Sriburi R., Supasa S., Panyadee N., Songjaeng A., Jairungsri A., et al. 2004. Alterations of pr-M cleavage and virus export in pr-M junction chimeric dengue viruses. *Journal of Virology*, 78 (5): p. 2367-2381.

- King C.A., Anderson R., and Marshall J.S. 2002. Dengue Virus Selectively Induces Human Mast Cell Chemokine Production. *Journal of Virology*, 76 (16): p. 8408-19.
- King C.A., Marshall J.S., Alshurafa H., and Anderson R. 2000. Release of Vasoactive Cytokines by Antibody-Enhanced Dengue Virus Infection of a Human Mast Cell/Basophil Line. *Journal of Virology*, 74 (15): p. 7146-7150.
- Kliks S., Nisalak A., Brandt W.E., and Burke D.S. 1988. Evidence that Maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. *American Journal of Tropical Medicine and Hygiene*, 40: 444-451.
- Konishi E., Terazawa A., and Imoto J. 2003. Simultaneous immunization with DNA and protein vaccines against Japanese encephalitis or dengue synergistically increases their own abilities to induce neutralizing antibody in mice. *Vaccine*, 21 (17-18): p. 1826-1832.
- Kunkel T.A. 1985. Rapid and efficient site-specific mutagenesis without phenotypic selection. *Proc. Natl. Acad. Sci. USA*. 82: p. 488-492.
- Kuno G. 1997. Factors influencing the transmission of dengue viruses. In D.J. Gubler and G. Kune: *Dengue and Dengue Hemorrhagic Fever*. Cambridge: University press. p. 61-80.
- Kurane I, Innis B.L., Hoke C.H. Jr, Eckels K.H., Meager A., Janus J., et al. 1995. T cell activation in vivo by dengue virus infection. *J Clin Lab Immunol.*, 46 (1): p. 35-40.
- Kurane I. and Ennis F.A. 1997. Immunopathogenesis of dengue virus infections. In D.J. Gubler and G. Kune: *Dengue and Dengue Hemorrhagic Fever*. Cambridge: University press. p. 273-290.
- Kurane I., Innis B.L., Nimmannitya S., Nisalak A., Rothman A.L., Livingston P.G., et al. 1990. Human immune responses to dengue viruses. *Southeast Asian J Trop Med Public Health*, 21 (4): p. 658-62.
- Lai C.J. and Monath T.P. 2003. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis. *Adv Virus Res.*, 61:469-509.
- Leitmeyer K.C., Vaughn D.W., Watts D.M., Salas R., Villalobos I., de Chacon, et al. 1999. Dengue virus structural differences that correlate with pathogenesis. *J Virol.*, 73(6): p. 4738-47.

- Leonard E Munstermann. 1995.
<http://klab.agsci.colostate.edu/aegypti/aegypti.html>, 05-05-1004.
- Libraty D.H., Pichyangkul S., Ajariyakhajorn C., Endy T.P., and Ennis F.A. 2001. Human Dendritic Cells Are Activated by Dengue Virus Infection: Enhancement by Gamma Interferon and Implications for Disease Pathogenesis. *Journal of Virology*, 75 (8): p. 3501-3508.
- Libraty D.H., Endy T.P., Houg H.S.H, Green S., Kalayanarooj S., Suntayakorn S., et al. 2002. Differing Influences of Virus Burden and Immune Activation on Disease Severity in Secondary Dengue-3 Virus Infections. *The Journal of Infectious Diseases*, 185: p. 1213-1221.
- Lin Y.W., Wang K.J., Lei H.Y., Lin Y.S., Yeh T.M., Liu H.S., et al. 2002. Virus Replication and Cytokine Production in Dengue Virus-Infected Human B Lymphocytes. *Journal of Virology*, 76 (23): p. 12242-12249.
- Lindenbach B.D. and Rice C.M. 1999. Genetic interaction of Flavivirus nonstructural protein NS1 and NS4A as a determinant of replicase function. *Journal of Virology*, 73 (6): p. 4611-4621.
- Littau R., Kurane I., and Ennis F.A. 1990. Human IgG receptor II mediates antibody-dependent enhancement of dengue virus infection. *The Journal of Immunology*, 144: p. 3183-3186.
- Livingston P.G., Kurane I., Lai C.J., Bray M., and Ennis F.A. 1994. Recognition of envelope protein by dengue virus serotype-specific human CD4+ CD8-cytotoxic T-cell clones. *J Virol.*, 68 (5): p. 3283-8.
- Loke H., Bethell D.B., Phuong C.X.T., Dung M., Schneider J., White N.J., et al. 2001. Strong HLA Class I – Restricted T Cell Responses in Dengue Hemorrhagic Fever: A Double-Edged Sword?. *The Journal of Infectious Diseases*, 184: p. 1369-1373.
- Lopez Antunano F.J. and Mota J. 2000. Development of immunizing agents against dengue. *Rev Panam Salud Publica.*, 7 (5): p. 285-92.
- Lu Y., Raviprakash K., Leao I.C., Chikhlikar P.R., Ewing D., Anwar A., et al. 2003. Dengue 2 PreM-E/LAMP chimera targeted to the MHC class II compartment elicits long-lasting neutralizing antibodies. *Vaccine*, 21 (17-18): p. 2178-2189.
- Mady B.J., Erbe D.V., Kurane I., Fanger M.W., and Ennis F.A. 1991. Antibody dependent enhancement of dengue virus infection mediated by bispecific antibodies against cell surface molecules other than Fcγ receptors. *The Journal of Immunology*, 147: p. 3139-3144.

- Mangada M.M, Endy T.P., Nisalak A., Chunsuttiwat S., Vaughn D.W., Libraty D.H, et al 2002. Dengue specific E cell responses in peripheral blood mononuclear cell obtained prior to secondary dengue virus infections in Thai school children. *The Journal of Infectious Diseases*, 185: p. 1697-1703.
- Mangada M.M., Ennis F.A., and Rothman A.L. 2003. Quantitation of dengue virus specific CD4+ T cells by intracellular cytokine staining. *Journal of Immunological Methods*, 284 (1-2): p. 89-97.
- Marianneau P., Cardona A., Edelman L., Deubel V., and Despres P. 1997. Dengue virus replication in human hepatoma cells activates NF-kappaB which in turn induces apoptotic cell death. *J. Virol.*, 71 (4): p. 3244-3249.
- Markoff L., Pang X.W., Hough H.S., Falgout B., Olsen R., Jones E., et al. 2002. Derivation and Characterization of a Dengue Type 1 Host Range-Restricted Mutant Virus That Is Attenuated and Highly Immunogenic in Monkeys. *Journal of Virology*, 76 (7): p. 3318-3328.
- Martínez-Barragán J. and del Angel R.M. 2001. Identification of a Putative Coreceptor on Vero Cells That Participates in Dengue 4 Virus Infection. *Journal of Virology*, 75 (17): p. 7818-27.
- Matusan A.E., Pryor M.J., Davidson A.D., and Wright P.J. 2001. Mutagenesis of the *Dengue Virus Type 2* NS3 Protein within and outside Helicase Motifs: Effects on Enzyme Activity and Virus Replication. *Journal of Virology*, 75 (20): p. 9633-43.
- McBride W.J.H. and Bielefeldt-Ohmann H. 2000. Dengue viral infections; pathogenesis and epidemiology. *Microbes and Infection*, 2: p. 1041-1050.
- Men R., Bray M., Clark D., Chanock R.M., and Lai C.J. 1996. Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. *J. Virol.*, 70 (6): p. 3930-37.
- Modis Y., Ogata S., Clements D., and Harrison S.C. 2003. A ligand-binding pocket in the dengue virus envelope glycoprotein. *PNAS*, 100 (12): p. 6986-91.
- Modis Y., Ogata S., Clements D., and Harrison S.C. 2004. Structure of the dengue virus envelope protein after membrane fusion. *Nature*, 427: p. 313 – 319.
- Moreno-Altamirano M.M, Sanchez-Garcia F.J., and Munoz M.L. 2002. Non Fc receptor mediated infection of human macrophages by dengue virus serotype 2. *Journal of General Virology*, 82: p.1123-1130.

- Muhareva R. 2004. Belajar dari wabah virus dengue. <http://www.kompas.com/kompas-cetak/0403/12/opini.htm> , 13-03-2004.
- Mune M., Rodriguez R., Ramirez R., Soto Y., Sierra B., Rodriguez Roche R., et al. 2003. Carboxy-terminally truncated Dengue 4 virus envelope glycoprotein expressed in *Pichia pastoris* induced neutralizing antibodies and resistance to Dengue 4 virus challenge in mice. *Arch Virol.*, 148 (11): p. 2267-73.
- PAHO. Facing the dengue threat: a blueprint for action. <http://www.paho.org/English/HCP/HCT/VBD/new-generation-bp.pdf> , 27-03-2004.
- Pang X.W., Zhang M.J, and Dayton A.I. 2001. Development of dengue virus replicons expressing HIV-1 gp120 and other heterologous genes: a potential future tool for dual vaccination against dengue virus and HIV. *BMC Microbiol.*, 1 (1): 28.
- Pang X.W., Zhang M.J., and Dayton A.I. 2001. Development of Dengue virus type 2 replicons capable of prolonged expression in host cells. *BMC Microbiol.*, 1 (1): p. 18.
- Polo S., Ketner G., Levis R., and Falgout B. 1997. Infectious RNA transcripts from full-length Dengue virus type 2 cDNA clones made in yeast. *J. Virol.*, 71 (7): p. 5366-74.
- Pugachev K.V., Guirakhoo F., Ocran S.W., Mitchell F., Parsons M., Penal C., et al. 2004. High Fidelity of Yellow Fever Virus RNA Polymerase. *Journal of Virology*, 78 (2): p. 1032-1038.
- Pugachev K.V., Guirakhoo F., Trent D.W., Monath T.P. 2003. Traditional and novel approaches to flavivirus vaccines. *Int J Parasitol.*, 33 (5-6): p. 567-82.
- Putnak R., Fuller J., Vanderzanden L., Innis B.L., and Vaughn D.W. 2003. Vaccination of Rhesus Macaques against Dengue-2 Virus with A Plasmid DNA Vaccine Encoding The Viral Pre-Membrane and Envelopes Genes. *Am. J. Trop. Med. Hyg.*, 68 (4): p. 469-476.
- Rabablert J., Dharakul T., Yoksan S., Bhamarapravati N. 2000. Dengue virus specific T cell responses to live attenuated monovalent dengue-2 and tetravalent dengue vaccines. *Asian Pac J Allergy Immunol.*, 18 (4): p. 227-35.
- Raviprakash K., Ewing D., Simmons M., Porter K.R., Jones T.R., Hayes C.G., et al. 2003. Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene

- increases immunogenicity and protection from virus challenge in Aotus monkeys. *Virology*, 315 (2): p. 345-52.
- Rey F.A. 2003. Dengue virus envelope glycoprotein structure: New insight into its interactions during viral entry. *PNAS*, 100 (12): p. 6899-6901.
- Rico-Hesse R. 2003. Microevolution and virulence of dengue viruses. *Adv Virus Res.*, 59: p. 315-41.
- Roehrig J.T. 1997. Immunochemistry of dengue viruses. In D.J. Gubler and G. Kune: *Dengue and Dengue Hemorrhagic Fever*. Cambridge: University press. p. 199-219.
- Rothman A.L. 1997. Viral pathogenesis of dengue infection. In D.J. Gubler and G. Kune: *Dengue and Dengue Hemorrhagic Fever*. Cambridge: University press. p. 245-271.
- Rothman A.L. 2004. Dengue: defining protective versus pathologic immunity. *J Clin Invest.* 113 (7): p. 946-951.
- Rothman A.L., Kanesa-athan N., West K., Janus J., Saluzzo J.F., and Ennis F.A. 2001. Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine. *Vaccine*, 19 (32): p. 4694-9.
- Rothman A.L., Kurane I., and Ennis F.A. 1996. Multiple specificities in the murine CD4+ and CD8+ T-cell response to dengue virus. *J Virol.*, 70 (10): p. 6540-6.
- Rothman A.L., Kurane I., Lai C.J., Bray M., Falgout B., Men R. and Ennis F.A. 1993. Dengue virus protein recognition by virus-specific murine CD8+ cytotoxic T lymphocytes. *Journal of virology*, 67 (2): p. 801-806
- Sabchaeron A., Lang J., Chathavanich P., Yoksan S., Forrat R., Attanath P., et al. Safety and Immunogenicity of Tetravalent Live Attenuated Dengue Vaccines In Thai Adult Volunteers: Role of Serotype Concentration, Ratio, and Multiple Doses. *Am. J. Trop. Med. Hyg.* 66 (3): p. 264-272.
- Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., et al. 2004. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. *Pediatr Infect Dis J.*, 23 (2): p. 99-109.
- Salas-Benito J.S. and del Angel R.M. 1997. Identification of two surface proteins from C6/36 cells that bind Dengue type 4 virus. *J. Virol.*, 71 (10): p. 7246-52.

- Sardelis M.R., Edelman R., Klein T.A., Innis B.L., Putnak J.R., Jones J.W., et al. 2000. Limited Potensial For Transmission Of Live Dengue Virus Vaccine Candidates By *Aedes Aegypti* and *Aedes Albopictus*. *Am. J. Trop. Hyg.*, 62 (6): p 698-704.
- Schmaljohn A.L and McClain D. 2001. Alphaviruses (Togaviridae) and Flaviviruses (Flaviviridae). <http://gsbs.utmb.edu/microbook/ch054.htm>, 05-05-1004.
- Shresta S., Kyle J.L., Snider H.M., Basavapatna M., Beatty P.R., and Harris E. 2004. Interferon-Dependent Immunity Is Essential for Resistance to Primary Dengue Virus Infection in Mice, Whereas T- and B-Cell-Dependent Immunity Are Less Critical. *Journal of Virology*, 78 (6): p. 2701-2710.
- Simon S., Saputra E.J., dan Nirmalasari O. 2004. Dengue hemorrhagic fever: an Indonesian perspective. *Majalah Kedokteran Atma Jaya*, 3 (1): p. 37-49
- Soedarmo S.P. 1998. Masalah demam berdarah dengue di Indonesia. In Sri Rezeki H. Hadinegoro dan Hindra Irawan Satari: *Demam berdarah dengue*. Jakarta: FKUI. p.1-31.
- Soegijanto S. 2004. Aspek imunologi penyakit demam berdarah dengue. In Soegeng Soegijanto: *Demam berdarah dengue: tinjauan dan temuan baru di era 2003*. Surabaya: Airlangga University Press. p. 11-25.
- Soegijanto S., Rantam F.A., Soetjipto, Sudiana K., dan Priyatna Y. 2004. Mencermati vaksin dengue rekombinan protein E sebagai calon andalan vaksin di masa depan. In Soegeng Soegijanto: *Demam berdarah dengue: tinjauan dan temuan baru di era 2003*. Surabaya: Airlangga University Press. p.79-90.
- Sun W., Edelman R., Kanesa-Thasan N., Eckels K.H., Putnak J.R., King A.D., et al. 2003 Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. *Am J Trop Med Hyg.*, 69 (6 Suppl): p. 24-31.
- Tacio H.D. 2003. Dengue vaccine developed. <http://www.manilatimes.net/national/2003/aug/09/life/mainlif/html> , 09-08-2004.
- Tassaneeritthep B., Burgess T.H., Granelli-Piperno A., Trumpfheller C., Finke J., Sun W., et al. 2004. DC-SIGN (CD209) Mediates Dengue Virus Infection of Human Dendritic Cells. *The Journal of Experimental Medicine*, 197 (7): p. 823-829.

- Tim Penanggulangan DBD Departemen Kesehatan RI. 2004. Kasus Demam Berdarah Dengue (DBD) di Indonesia. <http://www.depkes.go.id/downloads/Buletin%20DBD%208%20Maret%2004.pdf>, 01-10-2004
- Trent D.W., Kinney R.M., and Huang C.Y.H. 1997. Recombinant dengue virus vaccine. In D.J. Gubler and G. Kune: *Dengue and Dengue Hemorrhagic Fever*. Cambridge: University press. p. 61-80.
- Troyer J.M., Hanley K.A., Whitehead S.S., Strickman D., Karron R.A., Durbin A.P., and Murphy B.R. 2001. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. *Am J Trop Med Hyg.* 65 (5): p. 414-9.
- Valdés K., Alvarez M., Pupo M., Vázquez S., Rodríguez R., and Guzmán M.G. 2000. Human Dengue Antibodies against Structural and Nonstructural Proteins. *Clin Diagn Lab Immunol*, 7 (5): p. 856–857
- Van der Most R.G., Murali-Krishna K., Ahmed R., and Strauss J.H. 2000. Chimeric Yellow Fever/Dengue Virus as a Candidate Dengue Vaccine: Quantitation of the Dengue Virus-Specific CD8 T-Cell Response. *Journal of Virology*, 74 (17): p. 8094-8101.
- Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., et al. 1997. Dengue in the early febrile phase: viremia and antibody responses. *J Infect Dis*, 176 (2): p. 322-30.
- Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., et al. 2000. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. *J Infect Dis*, 181 (1): p. 2-9.
- Wang S., He R., and Anderson R. 1999. PrM- and Cell-Binding Domains of the Dengue Virus E Protein. *Journal of Virology*, 73 (3): p. 2547-2551.
- Warke R.V., Xhaja K., Martin K.J., Fournier M.F., Shaw S.K., Brizuela N., et al. 2003. Dengue Virus Induces Novel Changes in Gene Expression of Human Umbilical Vein Endothelial Cells. *Journal of Virology*, 77 (21): p. 11822-11832.
- Watanaveeradej V., Endy T.P., Samakoses R., Kerdpanich A., Simasathien S., Polpresert N., et al. 2003. Transplacentally Transferred Maternal-Infant Antibodies to Dengue Virus. *Am. J. Trop. Med. Hyg.*, 69(2): p. 123-128.

- Watts D.M., Porter K.R., Putvatana P., Vasquez B., Calampa C., Hayes C.G., et al. 1999. Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic. *Lancet*, 354 (9188): p. 1431-4.
- Whitehead S.S., Falgout B., Hanley K.A., Blaney, Jr. J.E., Markoff L., and Murphy B.R. 2003. A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3' Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys. *Journal of Virology*, 77 (2): p. 1653-1657.
- Whitehead S.S., Hanley K.A., Blaney J.E. Jr, Gilmore L.E., Elkins W.R., and Murphy B.R. 2003. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. *Vaccine*. 21(27-30): p. 4307-16.
- WHO, Dengue Vaccine Development, Status, challenges, and WHO priorities, <http://www.cidfa2004.sld.cu/conferencia/ver.php?id=91>, 06-05-2004.
- WHO, http://www.who.int/csr/don/2004_04_08/en/, 05-05-2004.
- World Health Organization, 1997, *Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd edition.* <http://www.who.int/emc/diseases/ebola/Denguepublication/001-11.pdf>, 27-4-2004.
- World Health Organization, 1997, <http://www.who.int/mediacentre/factsheets/fs117/en/>, 27 -4-2004.
- Wu S.F., Liao C.L., Lin Y.L., Yeh C.T., Chen L.K., Huang Y.F., et al. 2003. Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. *Vaccine*, 21 (25-26): p. 3919-29.